Analyzing Fulcrum Therapeutics (FULC) & Its Peers

Fulcrum Therapeutics (NASDAQ:FULC) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Fulcrum Therapeutics to similar businesses based on the strength of its valuation, profitability, institutional ownership, dividends, earnings, analyst recommendations and risk.

Profitability

This table compares Fulcrum Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-19.50%	-18.67%
Fulcrum Therapeutics Competitors	-12,319.70%	-407.93%	-30.95%

Valuation and Earnings

This table compares Fulcrum Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fulcrum Therapeutics	$80.00 million	-$74.88 million	-3.12
Fulcrum Therapeutics Competitors	$728.85 million	$11.28 million	-18.80

Fulcrum Therapeutics’ rivals have higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Fulcrum Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4	7	1	0	1.75
Fulcrum Therapeutics Competitors	9903	15310	45655	1602	2.54

Fulcrum Therapeutics presently has a consensus target price of $8.20, indicating a potential upside of 117.51%. As a group, “Biotechnology” companies have a potential upside of 126.26%. Given Fulcrum Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Fulcrum Therapeutics has less favorable growth aspects than its rivals.

Volatility and Risk

Fulcrum Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics’ rivals have a beta of -1.88, meaning that their average share price is 288% less volatile than the S&P 500.

Summary

Fulcrum Therapeutics rivals beat Fulcrum Therapeutics on 7 of the 13 factors compared.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.